CD274 and non-small cell lung carcinoma: (62) included 32 RWSs of programmed death-1/programmed death ligand-1 (PD-1/PD-L1) for advanced NSCLC, confirming the efficacy and safety results of PD-1/PD-L1 in real-world clinical practice were similar to those in clinical trials.